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Abstract: Staphylococcus aureus bacteremia is a common disease with a high risk of mortality 
and complications. An increasing proportion of cases are methicillin-resistant S.aureus (MRSA), 
and methicillin-resistance is being observed from both community-acquired bacteremias and in 
healthcare-associated infections. The duration of bacteremia and transesophageal echocardio-
graphic ﬁ  ndings are useful in predicting the likelihood of complications including endocarditis. 
Therapy with vancomycin has been the mainstay in the treatment of MRSA bacteremias, but 
is associated with a long duration of bacteremia on therapy and relapses. Loss of susceptibility 
to vancomycin, due to thickened cell walls and through the acquisition of the vanA gene, has 
been described. Daptomycin is newly approved lipopeptide that is highly bactericidal against 
most strains of MRSA. In a randomized trial, daptomycin was demonstrated to be effective in 
the treatment of S. aureus bacteremia and right-sided endocarditis. However treatment failures 
associated with isolates with daptomycin non-susceptibility are reported, and there is a correlation 
between isolates with reduced vancomycin susceptibility and reduced daptomycin susceptibility. 
Daptomycin is a useful alternative to vancomycin in the therapy of MRSA bacteremia and 
endocarditis. However the appropriate role of daptomycin in optimizing therapy with MRSA 
bacteremia and endocarditis remains to be elucidated.
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Introduction
In a national survey in the United States conducted in 2000–2001, Staphylococcus 
aureus infections were reported as a discharge diagnosis in 0.8% of all inpatients, and 
were associated with a ﬁ  ve-fold increased risk of in-hospital mortality (Noskin 2005). 
Methicillin-resistant S. aureus (MRSA) isolates were reported within a year of the 
initial use of semi-synthetic penicillins for the treatment of beta-lactamase producing 
staphylococci in 1960 (Jevons 1961). The incidence of methicillin resistance among 
S. aureus has been steadily rising over the last thirty years. In 2003, among nosoco-
mial infections in intensive care unit patients in the national nosocomial infections 
surveillance system report, the proportion of methicillin-resistant isolates among S. 
aureus strains comprised 59.5% of isolates (NNIS System Report 2004). The expand-
ing use of intravascular catheters, prosthetic devices, invasive procedures and broad 
spectrum antimicrobial use has resulted in an increased population of patients at risk 
for MRSA bacteremia.
Beginning in the mid-1990s, MRSA infections were also recognized in those 
without any of the healthcare associated risk factors, particularly as a cause of skin 
and soft-tissue infections, and included severe cases associated with bacteremia and 
mortalities. The incidence of community-acquired MRSA infections has steadily risen Therapeutics and Clinical Risk Management 2007:3(4) 676
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over the past ten years. The infections were initially recog-
nized more commonly in children, athletes, military recruits, 
Paciﬁ  c Islanders, Alaskan Natives, Native Americans, men 
who have sex with men, and prisoners (CDC 2004). Among 
adult patients with acute purulent skin and soft-tissue infec-
tions presenting in 2004 to academic emergency departments 
in the United States, 59% of the patients had infections due 
to MRSA (Moran 2006). Pulsed-ﬁ  eld type USA300 isolates 
accounted for 97% of these MRSA isolates. These strains 
contain the SCCmecIV element and usually the Panton-
Valentine leucocidin. Most hospital acquired MRSA contain 
SCCmec elements I, II, and III. At a large urban hospital 
in Atlanta, Georgia, 6.79 per 1000 hospital admissions 
were associated with a MRSA bacteremia (Seybold 2006). 
Of these patients, 8% had community-acquired infections 
with no health care associated risk factors, 42% were noso-
comial with onset of bacteremia  48 hours after hospital 
admission, and 50% were community-onset but had health-
care-associated risk factors. USA300 genotype was found in 
all of the patients without healthcare-associated risk factors, 
and in 20% of the nosocomial isolates, indicating that the 
USA300 genotype which is commonly associated with com-
munity-acquired MRSA infections also has now emerged as 
a pathogen in nosocomial disease.
S. aureus bacteremia
Studies have suggested a crude in-hospital mortality rate 
for MRSA bacteremia of 22 to 24.5%, and an attributable 
mortality of 12.2% (Khatib 2006, Seybold 2006). Although 
studies have reported higher mortality rates with MRSA 
compared to methicillin-susceptible strains (odds ratio [OR] 
1.93, 95% conﬁ  dence interval [CI] 1.54–2.42) (Cosgrove 
2003), this may represent differences in the host or efﬁ  cacy 
of treatment and not necessarily related to enhanced viru-
lence associated with susceptibility to methicillin. Animal 
models have suggested that the presence of the mecA gene 
complex per se is not associated with increased virulence of 
the organism (Voyich 2005).
In addition to a high mortality rate, complications associ-
ated with S. aureus bacteremia are common. Complications 
reported in a prospective study of 724 patients with S. aureus 
bacteremia in a single academic medical center include endo-
carditis in 89 (12%), septic arthritis in 54 (7.5%), deep tissue 
abscesses in 41 (5.7%) vertebral osteomyeltis in 22 (3.0%), 
epidural abscesses in 18 (2.5%), septic thrombophlebitis in 
17 (2.3%), psoas abscess in 13 (1.7%), and meningitis in 12 
(1.7%). Seventy patients (9.7%) developed a recurrent S. 
aureus infection, including 49 (6.7%) recurrent bacteremias 
(Fowler 2003). In another prospective study at six teaching 
hospitals, 66 of 505 (13%) consecutive patients with S. 
aureus bacteremia were found to have endocarditis, including 
21% of patients with community acquired infections (11 of 
95), 5% of nosocomial infections (10 of 204), and 12% of 
those on hemodialysis (11 of 95). Forty-two of 505 patients 
(8.3%) had recurrent infections, of which 79% had relapse 
with the same organism documented by pulsed-ﬁ  eld gel 
electrophoresis. The median time relapse was 36 days (range 
10–190 days). Thirty-one percent of the cases of endocarditis 
were due to MRSA (Chang 2003b).
Identifying complications and providing appropri-
ate therapy to prevent relapse are key elements in the 
management of S. aureus bacteremia. The presence of com-
munity-acquired bacteremia (OR 3.08; 95% CI, 1.80–5.28), 
skin examination ﬁ  ndings suggestive of the presence of acute 
infection (petechiae, vasculitis, infarcts, ecchymoses and 
pustules) (OR 1.80; 95% CI 1.10–2.95), positive follow-up 
blood cultures obtained 48 to 96 hours after antimicrobial 
administration (OR 4.94; 95% CI 3.37–7.25), and persis-
tent fever at 72 hours (OR 2.00; 95% CI, 1.36–7.25) are all 
predictive of the presence of complications in a multivariate 
model (Fowler 2003). However 16% of patients without 
any of these risk factors still had complicated infections. In 
a study conducted at six teaching hospitals, the following 
risk factors are associated with endocarditis among pa-
tients with S. aureus bacteremia in a multivariate analysis: 
native valve disease (OR 4.5; 95% CI 2.0–9.9), the pres-
ence of a prosthetic valve (OR 10.5; 95% CI ,7.5–43.7), 
positive blood cultures on appropriate therapy for  3days 
(OR 7.4; 95% CI, 3.3–16.6), intravenous drug use (OR 
3.2; 95% CI, 1.2–8.6) , and an unidentiﬁ  able portal of 
entry (OR 3.3; 95% CI 1.3–6.6), history of prior endocarditis 
(OR 10.0; 95% CI 2.0–50.0), community acquisition (OR 
2.9; 95% CI 1.4–4.9), and nonwhite race (OR 2.5; 95% CI 
1.2–5.3) (Chang 2003a). MRSA endocarditis was more 
likely in those with persistent bacteremia and with serum 
creatinine  2 mg/dl. Native valve disease and cirrhosis 
were signiﬁ  cantly associated with a relapse of bacteremia 
(Chang 2003b).
The duration of bacteremia is associated with meta-
static infections and complications. Complications and 
metastatic infections increased from 6.6% among those 
with bacteremias persisting from 1 to 2 days, to 24.0% 
among those with bacteremias for 3 days, and 37.7% 
among those with bacteremias persisting  4 days (p = 0.05) 
(Khatib 2006). Of note is that there may not be a strong 
correlation between the duration of fever and bacteremia Therapeutics and Clinical Risk Management 2007:3(4) 677
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(r = 0.121, p = 0.094), and bacteremia may continue after 
resolution of fever in more than half of cases (Khatib 2006). 
Persistent bacteremia for more than 3 days correlates with 
the presence of endovascular sources, having a cardiovascu-
lar prosthesis, a metastatic infection and diabetes. A length of 
time of incubation before detection of a positive blood culture 
using a blood culture system that monitors CO2 production 
every 10 minutes (time to positivity) of less than 14 hours 
is an independent predictor of an endovascular source of 
infection, prolonged bacteremia, metastatic infection, and 
attributable mortality (Khatib 2005). Because of concerns of 
unrecognized endocarditis among patients with intravascular 
catheter-associated S. aureus bacteremia, the Infectious Dis-
eases Society of America, in conjunction with the American 
College of Critical Care Medicine and the Society for Health-
care Epidemiology of America has recommended routine use 
of transesophageal echocardiography (TEE). TEE is helpful 
in the diagnosis of endocarditis, is more sensitive than trans-
thoracic echocardiography, and has been demonstrated to be 
cost-effective compared to empiric short-course (2 week) or 
long course (4 week) therapy (Rosen 1999). The use of TEE 
in this setting has not been studied prospectively, however, 
and it remains unclear if empiric short-course therapy can be 
safely utilized without a TEE among patients with a remov-
able focus of infection and without the risk factors associated 
with endocarditis and complications identiﬁ  ed above.
Endocarditis
The large International Collaboration on Endocarditis (ICE) 
merged database study has suggested that S. aureus has 
become the most common microbiologic cause of endocar-
ditis observed in tertiary referral centers, occurring in 31.6% 
of cases of endocarditis (Fowler 2005). Compared to non-S. 
aureus endocarditis, patients with S. aureus endocarditis 
were more likely to have intravenous drug use (OR 9.3; 95% 
CI 6.3–13.7), a ﬁ  rst clinical presentation less than 1 month 
after ﬁ  rst symptoms (OR 5.1; 95% CI 3.2–8.2), health-care 
associated infections (OR 2.9; 95% CI 2.–3.8), persistent 
bacteremia deﬁ  ned as positive blood cultures more than 
12 hours apart or all of three or a majority of four or more 
separate blood cultures, with ﬁ  rst and last drawn at least one 
hour apart (OR 2.3; 95% CI 1.2–2.6), presence of a presumed 
intravascular device as a source (OR 1.7; 95% CI 1.2–2.3), a 
stroke (OR 1.6; 95% CI 1.2–2.3), and diabetes mellitus (OR 
1.3; 95% CI 1.1–1.8). In-hospital mortality was 22.4%, and 
was higher among those with health-care associated disease, 
and among those with cardiac devices. 27.4% of cases were 
due to MRSA, and patients with MRSA endocarditis had 
higher rates of persistent bacteremia compared to those 
with MSSA (42.6% vs 8.8%, p   0.001), a presumed intra-
vascular device as a source (60.3% vs 30.7%, p   0.001), 
chronic immunosuppressive therapy (17.7% vs 3.5%, 
p   0.001), and diabetes mellitus (34.0% vs 18.0%, 
p   0.001). Within the ICE study among patients with S. 
aureus native valve endocarditis, characteristics associated 
with mortality in a multivariate analysis included increasing 
age (OR, 1.38; 95% CI, 1.15–1.66), presence of heart failure 
(OR, 3.90; 95% CI 2.27–6.68), periannular abscess (OR, 
2.34: 95% CI, 1.05–5.64), and an aortic valve vegetation 
(OR, 1.91; 95% CI, 1.00–3.66). Receiving surgical therapy 
was associated with reduced in-hospital mortality (OR 0.43; 
95% CI 0.24–0.79) (Miro 2005). Among patients with pros-
thetic valve endocarditis in the ICE study, overall mortality 
was 47.5%. Among those with prosthetic valve endocarditis, 
stroke appeared to be associated with a higher mortality in 
multivariate analysis (OR 30.4, 95% CI 0.8–11.6, p = 0.09), 
and although early valve replacement was not associated 
with improved survival in the whole population, there was 
a trend towards it beneﬁ  ting those who developed conges-
tive heart failure and/or an intracardiac abscess (28.6% 
mortality vs 53.3%, p = 0.09) (Chirouze 2004). American 
Heart Association guideline indications for surgical therapy 
in patients with MRSA infective endocarditis include conges-
tive heart failure, infections with strains not fully susceptible 
to vancomycin, persistent bacteremia greater than one week 
on therapy, one or more embolic events during the ﬁ  rst two 
weeks of therapy, valvular dehiscence, perforation, rupture 
or ﬁ  stula formation, perivalvular abscess greater than 1 cm, 
anterior leaﬂ  et of mitral value vegetation size greater than 
1 cm, and an increase in vegetation size despite appropriate 
antimicrobial therapy (Baddour 2005).
Therapy of MRSA bacteremia 
and endocarditis with vancomycin
Vancomycin is the drug of choice as recommended by current 
guidelines by the Infectious Diseases Society of America 
in the treatment of catheter-associated MRSA bacteremia 
(Mermel 2001), by the American Heart Association and Infec-
tious Diseases Society in the treatment of MRSA endocarditis 
(Baddour 2005), and by the British Society for Antimicrobial 
Chemotherapy in the treatment of MRSA bacteremia (Gem-
mell 2006). However there are concerns about the efﬁ  cacy of 
vancomycin. Compared to nafcillin, vancomycin has slower 
in vitro killing of S. aureus when measured at 24 hours and 
vancomycin therapy for methicillin-susceptible S. aureus 
endocarditis in intravenous drug users was associated with Therapeutics and Clinical Risk Management 2007:3(4) 678
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a higher than expected failure rate compared to historical 
controls treated with beta-lactams (Small and Chambers 
1990). In a study of MRSA endocarditis, the mean duration 
of bacteremia on vancomycin therapy was seven days (95% 
CI 6–11). The duration of bacteremia was similar (9 days) 
when combining vancomycin with rifampin  (95% CI 6–13) 
(Levine 1991). In two prospective studies of methicillin-
susceptible S. aureus bacteremia, nafcillin was superior to 
vancomycin in preventing persistent bacteremia (62.5% vs 
52.6%, p = 0.04) or relapse (OR, 6.5; 95% CI, 1.0–52.8; p 
  0.048) (Chang 2003b; Khatib 2006).
In addition to slow or inadequate response rates associ-
ated with vancomycin therapy, more recently concerns have 
emerged regarding the development of strains of S. aureus 
that are not fully susceptible to vancomycin. In 1996 the 
ﬁ  rst clinical isolate of S. aureus with intermediate suscep-
tibility to vancomycin, vancomycin intermediate S.aureus 
(VISA) was noted in Japan. As of 2002, eight cases had 
been identiﬁ  ed, and the number of cases has been steadily 
growing. In 2002 the ﬁ  rst clinical case of S. aureus with 
full resistance to vancomycin occurred (CDC 2002). In 
addition a growing concern regarding poor vancomycin 
response rates among isolates with a MIC of 4 µg/ml prompt-
ed a change by the Clinical and Laboratory Standards Institute 
in deﬁ  ning vancomycin susceptibility to isolates with a MIC 
of  2 µg/ml, intermediate susceptibility for isolates of 4–8 
µg/ml, and resistance for isolates  16 µg/ml (CLSI 2006). 
VISA strains have developed thickened cell walls, and van-
comycin becomes clogged within the cell wall, preventing 
it from reaching its target in the cytoplasmic membrane (Cui 
2006). Another feature of VISA strains is their association 
with group II polymorphism at the accessory gene regula-
tor (agr) locus (Sakoulas 2002). Vancomycin efﬁ  cacy has 
also been inversely correlated with MIC values within the 
susceptible range, and the higher failure rates among the 
isolates with MIC values of 2µg/ml has been correlated with 
this polymorphism. In one study the vancomycin response 
rates was 61% among patients with isolates with a MIC of 
0.5 µg/ml, 28% among patients with a MIC of 1.0 µg/ml, 
and 11% among isolates with a MIC of 2 µg/ml (Moise-
Broder 2004). In another study the ﬁ  nal response rate with 
vancomycin therapy was 85% among isolates with MIC1 
µg/ml and 62% among isolates with a MIC of 2 µg/ml even 
among patients who reached a trough level of vancomycin 
of  15 µg/ml (p = 0.02). Attainment of a target vancomy-
cin trough level of  15 µg/ml vancomycin did not improve 
ﬁ  nal response rates among isolates with a MIC of 2 µg/ml 
(Hidayat 2006). Vancomycin-resistant S.aureus (VRSA) 
isolates do not have enlarged cell walls, but have acquired 
the vanA vancomycin resistance gene from enterococci, 
which alters the vancomycin target (Cui 2006, CDC 2002). 
Resistance in these isolates is due to the synthesis of an alter-
native terminal peptide D-ala-D-lac instead of D-ala-D-ala. 
Vancomycin is unable to bind to D-ala-D-lac.
Daptomycin: mode of action, 
resistance, pharmacokinetics, 
and pharmacodynamics
Because of concerns about the utility of vancomycin in the 
treatment of MRSA, development of additional agents has 
been undertaken by the pharmaceutical industry. Dapto-
mycin is a cyclic lipopeptide, derived from a fermentation 
product of Streptomyces roseosporus initially discovered by 
Eli Lilly and Company in the early 1980s. It has a unique 
mechanism of action, and is only active against Gram-posi-
tive bacteria. It acts at the cytoplasmic membrane, binding 
but not penetrating the membrane via a calcium-dependent 
insertion of its lipid tail. It forms an ion-conduction struc-
ture, resulting in an efﬂ  ux of ions, including potassium. 
Cell death occurs associated with widespread inhibition of 
synthesis of DNA, RNA, and protein, but cell lysis and re-
lease of large molecules from the cytoplasm does not occur. 
The activity of daptomycin is dependent on the presence of 
calcium. It is 2–4 fold more active in Mueller-Hinton media 
supplemented to 50 µg/ml Ca2+ per mL, compared to the 
usual 20–25 µg/ml in usual resistance testing (Carpenter 
and Chambers, 2004).
Prior to 2003, there had been no reports of initial clinical 
isolates of S. aureus without previous exposure to daptomy-
cin that were resistant to daptomycin, although mutants of 
S. aureus resistant to daptomycin could be derived by serial 
passage in liquid media containing incremental subinhibitory 
concentrations (Carpenter and Chambers, 2004). With the 
emergence of an increasing number of strains of S. aureus 
with vancomycin intermediate susceptibility, a correlation 
has been noted between acquisition of vancomycin interme-
diate susceptibility and non-susceptibility of daptomycin. 
Daptomycin susceptibility is deﬁ  ned as a MIC of  1 µg/ml 
(CSLI 2006). Among S. aureus strains fully susceptible to 
vancomycin, 97% are susceptible to daptomycin. However 
among strains with a vancomycin MIC of 4 µg/ml, only 
20% are susceptible to daptomycin, and among strains with 
a vancomycin MIC of 8–16 µg/ml only 7% are susceptible 
to daptomycin (Patel 2006). All 5 VRSA isolates tested 
with vancomycin MIC  32 µg/ml remain susceptible to Therapeutics and Clinical Risk Management 2007:3(4) 679
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daptomycin. Daptomycin heteroresistance is also found 
among strains that develop vancomycin heteroresistance 
during treatment with vancomycin, even when the MIC of 
the organisms remains within the susceptible range. In vitro 
killing assays demonstrate less rapid killing of these heterore-
sistant isolates (Sakoulas 2006). Cui, et al also found a strong 
correlation (R = 0.814, p   0.0001) between daptomycin 
reduced susceptibility and vancomycin resistance among 
VISA strains, and correlated this loss of susceptibility with 
the degree of cell wall thickening (R = 0.883, p   0.0001) 
(Cui 2006). They postulated that the mechanism of the loss 
of daptomycin susceptibility was due to the inability of 
daptomycin, which has a molecular weight of 1,620, to pass 
through the physical barrier of the enlarged cell wall. VRSA 
isolates which have vancomycin resistance as a result of 
acquisition of the vanA gene and have normal size cell walls 
remain susceptible to daptomycin. In clinical isolates, prior 
patient exposure to vancomycin is associated with isolates 
with a small but statistically signiﬁ  cant rise in daptomycin 
MIC (mean 0.599 vs 0.726 µg/ml p = 0.019) even among 
strains that remain within the susceptible range (Moise-
Broder 2006).
Daptomycin exhibits linear pharmacokinetics at doses 
up to 12 mg/kg with a maximum concentration (Cmax)of 93.9 
µg/ml, minimum concentration (Cmin ) of 6.7 µg/ml, and area 
under the concentration curve (AUC0–tau) of 631.8 µg·h/ml 
at steady state with a dose of 6 mg/kg per day. The half-life 
of approximately 8 hours, volume of distribution of 100 ml/
kg, and protein binding of 90–93% are independent of dose 
(Benvenuto 2006). Protein binding is reduced to 84–88% 
among patients with a creatinine clearance of less than 20 
ml/min. Approximately 78% of daptomycin is excreted via 
the kidney, two-thirds of which is intact drug (Carpenter 
and Chambers 2004). It is not extensively metabolized. The 
dose for bacteremia and right-sided endocarditis is 6 mg/kg 
administered once daily. The dose for skin and soft tissue 
infections is 4 mg/kg administered once daily. For patients 
with creatinine clearance of  30 ml/minute the same dose 
is administered every 48 hours. It should be administered 
after hemodialysis because approximately 15% of the dose 
is removed by 4h of hemodialysis. No clinically signiﬁ  cant 
drug interactions have been identiﬁ  ed. No dose adjustment 
is needed for mild to moderate hepatic insufﬁ  ciency. Dosage 
has not been evaluated in severe hepatic insufﬁ  ciency.
Daptomycin is more rapidly bactericidal than vancomycin 
in vitro (Tally and DeBruin 2000). In vitro time-kill studies 
using exponential growth phase MRSA there is more than 
a 3 log10 fall in CFU/ml by only 2 hours at a 20 µg/ml con-
centration of daptomycin compared to a less than 1 log10 fall 
with 20 µg/ml vancomycin (Lamp 1992). It has concentration 
dependent killing in vitro and in pharmacodynamic studies 
in mice (Tally and DeBruin 2000). Similarly in an in vitro 
pharmacodynamic model with simulated endocardial vegeta-
tions it had concentration dependent killing, and against both 
a MRSA and a MSSA strain was more rapidly bactericidal 
than vancomycin over a 4 to 96 hour time course (Tsuji and 
Rybak 2005). It produces a post-antibiotic effect (PAE) of 
over 6 hours at 16 µg/ml that is concentration dependent 
compared to a 1.3–1.8 hour PAE of vancomycin that is non-
dose-dependent (Hanberger 1991). Unlike vancomycin, it 
maintains high level bactericidal activity when tested against 
a high inoculum of 9.5 log 10 cfu/g of MRSA in an in vitro 
simulated endocardial vegetation model, and has activity 
against stationary phase growth organisms (LaPlante 2004, 
French 2006). Similar to vancomycin, it is less active in 
more acidic pH within pH ranges of 6.4 to 8.0 (Lamp 1992). 
The clinical relevance of this ﬁ  nding in the management of 
infections associated with intracellular organisms within 
the phagolysosome or in the treatment of abscesses remains 
speculative. The addition of gentamicin to daptomycin is 
synergistic in some in vitro time-kill studies and in an in 
vitro pharmacodynamic model with simulated endocardial 
vegetations, but was not beneﬁ  cial in improving human 
serum bactericidal activity of daptomycin against MRSA 
(Tsuji and Rybak 2005; DeRyke 2006).
Clinical studies of efﬁ  cacy
The initial clinical studies of daptomycin were performed 
by Eli Lilly and Company. Efﬁ  cacy in small studies was 
comparable to conventional therapy in the treatment of skin 
and soft-tissue infections, and it was effective in 17 of 19 
patients with bacteremia treated with a 6 mg/kg load followed 
by 3 mg/kg every 12 h for up to 34 days (Tally and DeBruin 
2000). Daptomycin was dropped from further development 
by Lilly because of concerns regarding skeletal muscle toxic-
ity with higher-dose regimens when utilized every 12 hours, 
and failures among patients treated for S. aureus endocarditis 
(Lamp 1992). Cubist Pharmaceuticals, Inc. licensed dapto-
mycin from Lilly in 1997, and initiated clinical trials in 1999 
in patients with complicated skin and soft-tissue infections, 
community-acquired pneumonia, urinary tract infections, 
bacteremia and endocarditis utilizing once daily-dosing. 
Once daily dosing may increase the therapeutic-toxicity ratio 
because of the concentration dependent killing, prolonged 
post-antibiotic effect, and in animal models, less skeletal 
muscle toxicity associated with once-daily administration Therapeutics and Clinical Risk Management 2007:3(4) 680
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(Tally and DeBruin 2000). In the complicated skin and 
soft-tissue infection trial, among 902 evaluable patients, the 
83.4% clinical response with daptomycin given at 4 mg/kg 
every 24h was similar to the 84.2% response rate (95% CI 
for the difference, –4.0 to 5.6) with the comparator drugs 
(either vancomycin given at 1 gm every 12h or a penicillin-
ase-resistant penicillin given at 4–12 gm intravenously daily 
in divided doses). Among patients successfully treated, 63% 
of those required only 4–7 days of therapy and were able to 
switch to an oral drug at that time, compared to 33% of the 
comparator drug (p   .0001) (Arbeit 2004). Response rates 
were similar between daptomycin and the comparator arm 
among those who had infections with MRSA (21/28 [75%] 
vs 25/36, [69.4%], 95% CI –28.5 to17.4) and among those 
who received vancomycin as the comparator drug (90 of 
111 [81.1%] patients vs 127 of 172 [73.8%] patients, 95% 
CI –17.4 to 2.9). Studies in the treatment of pneumonia 
were halted when pooled data revealed that daptomycin was 
inferior to ceftriaxone (Carpenter and Chambers 2004). Dap-
tomycin has low concentrations in bronchial-alveolar lining 
ﬂ  uid and lung parenchyma, and is inactivated by surfactant 
(Silverman 2005). Daptomycin should not be utilized in the 
treatment of pneumonia. A phase III trial investigating the use 
of daptomycin in the treatment of complicated urinary tract 
infections due to gram-positive organisms was terminated 
early because of difﬁ  culty enrolling patients.
Daptomycin was evaluated for the treatment of S. aureus 
bacteremia and endocarditis in a recently published prospec-
tive randomized trial (Fowler 2006). The trial was open-
labeled, but an adjudication committee which was blinded to 
treatment arm determined outcome. Patients were excluded 
if their age was  18 years, they had a creatinine clearance 
less than 30 ml/min, known osteomyelitis, polymicrobial 
bacteremia, or pneumonia. Patients were randomized 1:1 to 
either daptomycin 6 mg/kg daily or standard therapy with 
either vancomycin 1 g every 12 hours (adjusted to renal 
function) or a penicillinase-resistant penicillin (nafcillin, 
oxacillin, or ﬂ  ucloxacillin) 2 g every 4 hours, depending 
on the results of methicillin susceptibility testing. Serum 
vancomycin levels were monitored according to standard 
practice of each participating site.
Length of therapy was determined by the investigator 
depending on the working diagnosis. Patients assigned to 
standard therapy and all patients with left-sided endocarditis 
were given gentamicin 1 mg/kg every 8h (adjusted to renal 
function) for the ﬁ  rst four days. Patients were required to 
undergo TEE within the ﬁ  rst ﬁ  ve days of therapy. Blood 
cultures were performed daily until negative, at the end of 
therapy, and at day 42. The primary outcome was clinical 
success at day 42, and failure at that time was deﬁ  ned as 
clinical failure (no response to the study drug on the basis 
of ongoing signs an symptoms of infection), microbiologic 
failure, death, failure to obtain blood culture, receipt of 
potentially effective non-study antimicrobial agent, or pre-
mature discontinuation of the study medication because of 
clinical failure, microbiologic failure, or an adverse event. 
The study was designed as a non-inferiority trial, and was 
powered to detect a difference of 20% between the two 
treatment groups.
MRSA was isolated in 89 of 235 (38%) of patients, 
and 53 (22.5%) of patients had endocarditis. The overall 
success rates was 53/120 (44.2%) in the daptomycin arm, 
and 48/115 (41.7)% in the comparator arm, including a 
37.7% (20/53) response among those that received van-
comycin, and 45.2% (28/62) among those that received 
an antistaphylococcal penicillin. The differences were 
not statistically significant, and there were no statistical 
differences among patients infected with MRSA (44.4% 
success with daptomycin and 31.8% with standard thera-
py, 95% CI –7.4 to 32.6), among those with complicated 
bacteremias, or endocarditis. Only 1 of 9 patients with 
left-sided endocarditis was treated successfully with 
daptomycin, compared to 2 of 9 treated successfully with 
the comparator arm. Among those infected with MRSA, 
the median time to clearance of bacteremia did not differ 
between the daptomycin arm and the comparator arm 
(8 days and 9 days, respectively, p = 0.25). 19 of 120 
patients (15.8%) had treatment failures due to persistent 
or relapsing S. aureus infections in the daptomycin arm 
compared to 11 of 115 patients (9.6%) in the standard 
therapy arm (p = 0.17). 8 patients (6.7%) had treatment-
related adverse events in the daptomycin arm compared to 
17 patients (14.8%) in the standard therapy arm (p = 0.06). 
Of the 19 patients in the daptomycin arm who had micro-
biologic failure, 6 had increases in daptomycin MICs to 
the non-susceptible range, and 5 of these isolates were 
MRSA. This represents 11% of the patients with MRSA 
treated with daptomycin. Overall gentamicin was ad-
ministered to 107 of 115 patients in the standard-therapy 
group (93%) and in 1 of 120 patients in the daptomycin 
group. In a substudy analysis, study drug MIC shifts to 
 2 µg/ml occurred in 7/120 patients treated with dapto-
mycin, and in 7/53 patients treated with vancomycin and 
gentamicin (Luperchio 2006). None of the vancomycin 
isolates had a shift to the non-susceptible range (4 µg/ml). 
Baseline MIC values did not predict MIC shifts. Patients Therapeutics and Clinical Risk Management 2007:3(4) 681
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with MIC shifts in both arms typically did not or could not 
receive appropriate adjunctive therapy, such as surgery 
or drainage of sequestered foci of infection, including 
osteomyelitis, and removal of indwelling prostheses or 
devices. Microbiologic treatment failure did not correlate 
with levels of plasma antimicrobials in either arm.
In a retrospective report of use of daptomycin in 
the treatment of bacteremia and endocarditis at one 
university-affiliated hospital and one regional hospital, 
eleven patients had MRSA bacteremia with or without 
endocarditis, and all were treated successfully with dap-
tomycin. Most of the patients had received vancomycin 
prior to initiation of daptomycin and had persistent bac-
teremia ( 5 days) on vancomycin prior to initiation of 
daptomycin (Segreti 2006). In a preliminary report from 
a multicenter retrospective observation chart review 
evaluating outcomes of patients receiving daptomycin, 
a 76% success rate was achieved among patients with 
endocarditis. Among patients with all infections, suc-
cess rates were lower among patients with creatinine 
clearance less than 30 ml/min (McKinnon 2006). There 
are case reports, especially among patients with osteo-
myelitis and endovascular infections who had previously 
failed therapy with vancomycin, that have failed therapy 
with daptomycin associated with bacteremia with isola-
tion of MRSA that developed reduced susceptibility to 
daptomycin (Hayden 2005; Vikram 2005; Mangill 2005; 
Paez 2006).
Safety
During the early development of daptomycin, dosing of 
daptomycin at 4 mg/kg every 12 hours resulted in myopathy 
in 2 of 5 subjects. An investigation in dogs found that the 
skeletal muscle myopathy was more related to the higher 
sustained trough concentration than the peak drug concen-
tration or the area under the curve (Oleson 1999). Along 
with the pharmacodynamic properties of the drug, this led 
to the development of daptomycin using once daily dos-
ing. In the complicated skin and soft tissue infection trial 
utilizing a dose of 4 mg/kg per day, elevations of creatinine 
kinase levels were found in 15 of 534 (2.8%) of patients in 
the daptomycin arm, and in 10 of 558 (1.8%) of patients in 
the comparator arm (Arbeit 2004). Only 1 of 534 patients 
receiving daptomycin had an elevation of creatinine kinase 
associated with weakness and muscle pain that was felt to 
be drug related. After discontinuation of the drug, symptoms 
resolved over the following 72 hours. In the bacteremia trial 
utilizing a 6 mg/kg per day dose, creatinine kinase elevations 
of  500 IU/L were observed in 11 of 116 (9.5%) of evaluable 
patients in the daptomycin group compared to 2 of 111 (1.5%, 
p = 0.02) in the standard-therapy group (Fowler 2006). 10 
of 120 (8.3%) patients receiving daptomycin stopped study 
drug because of a drug-related adverse event, compared to 
13 of 116 (11.2%, p = 0.51) in the standard-therapy group. 
Discontinuation of daptomycin was due to elevated creatinine 
kinase levels in 3 of 120 patients treated with daptomycin. 
Daptomycin induced rhabdomyolysis including rhabdomy-
olysis induced acute renal failure has now been reported in 
case reports (Edwards 2006, Kazory 2006). Patients receiving 
daptomycin should be monitored for signs and symptoms 
of myopathy and receive a weekly creatinine kinase level. 
Daptomycin should be discontinued in patients who develop 
an otherwise unexplained myopathy with elevated creatinine 
kinase levels ( 5 times the upper limit of normal or  1000 
IU/L) or an isolated increase in creatinine kinase  10 times 
the upper limit of normal. There were no reports of skeletal 
myopathy in a phase I trial of daptomycin dosed at 4 mg/kg/d 
among patients receiving concomitant simvastatin. In the 
bacteremia/endocarditis trial 5 of 22 patients who received 
prior or concomitant HMG-CoA reductase inhibitors and 
daptomycin developed creatine phosphokinase (CPK) 
elevations of  500 U/L. Consideration should be given to 
suspending HMG-CoA reductase inhibitors during therapy 
with daptomycin (Cubist 2006).
Other side-effects related to daptomycin are unusual 
and have not been associated with signiﬁ  cant increases in 
events compared to comparator arms in randomized trials. 
An exception is events related to the peripheral nervous 
system, including paresthesias, dysesthesia, and peripheral 
neuropathy, which was observed in 9.2% of patients receiving 
daptomycin in the bacteremia trial, compared to 1.7% of the 
comparator arm (p = 0.02). These events were felt to mild 
to moderate, and most were transient and resolved during 
continued treatment (Fowler 2006).
Keys in the therapy of bacteremia 
due to MRSA
Effective antimicrobial therapy should be initiated promptly 
after obtaining appropriate cultures, including at least 2 sets of 
blood culture from separate sticks, when there is a reasonable 
likelihood of MRSA bacteremia. Delays in therapy have been 
associated with higher mortality, especially among patients 
with higher APACHE II scores (Lodise 2003). Either vanco-
mycin or daptomycin should be initiated unless the source of 
bacteremia is due to pneumonia, in which case daptomycin Therapeutics and Clinical Risk Management 2007:3(4) 682
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should not be used. A thorough investigation should be 
performed to determine the source of the bacteremia, recog-
nizing the possibility of endocarditis, catheter and prosthetic 
device infections, septic arthritis, osteomyelitis (including 
vertebral osteomyeltis), epidural, psoas muscle or deep tissue 
abscesses, and septic thrombophlebitis, which may not be 
clinically obvious. Intravascular catheters that are potential 
sources of the bacteremia should be removed. Attempts at 
salvage of tunneled catheters in stable patients in whom there 
is no tunnel, pocket or exit-site infection and a negative trans-
esophageal echocardiogram using an antibiotic lock therapy 
have been suggested by guidelines, but in limited trials has 
been generally unsuccessful in infections due to S. aureus 
(Mermel 2001; Forun 2006). All attempts should be made 
to debride infected tissues, appropriately drain abscesses, 
and remove infected hardware. Patients with endocarditis, 
particularly left-sided endocarditis, should be considered 
for valve replacement based on current guidelines (Baddour 
2005). Blood cultures in all patients with bacteremia should 
be repeated every 72 hours until negative.
The duration of therapy for MRSA bacteremia is contro-
versial, and is dependent on the source of the bacteremia. 
Most authorities have recommended at least two weeks 
of intravenous therapy for S. aureus bacteremia (Mermel 
2001). However seven days of therapy may be adequate in 
patients with bacteremia due to a removable focus when 
the device is promptly removed, a transesophageal echocar-
diogram is negative, there are no heart valve abnormalities, 
no indwelling prosthetic devices, follow-up blood cultures 
at 72 hours are negative, and there are no features of 
metastatic infection (Fowler 1998). Patients with persistent 
bacteremias beyond 72 hours, those with osteomyelitis, 
septic thrombophletibis, infective endocarditis and deep 
tissue infections should be treated with four to six weeks 
of intravenous antibiotics.
Therapy of MRSA not fully susceptible to vancomycin 
also remains controversial. Vancomycin MICs between 2 and 
8 µg/ml have been correlated with daptomycin non-suscep-
tibility. Linezolid, quinupristin-dalfopristin, tigecycline and 
trimethoprim-sulfamethoxasole are alternatives for patients 
with VISA strains. High dose daptomycin at doses of up to 
12 mg/kg per day could be considered (Benenuto 2006), 
but would likely risk a greater chance for skeletal muscle 
toxicity. VRSA strains could be treated with daptomycin, 
with linezolid, quinupristin-dalfopristin, tigecycline and 
trimethoprim-sulfamethoxasole as alternatives, but among 
these only daptomycin and quinupristin-dalfopristin are 
bactericidal agents (Cha 2003). Of high controversy is the 
optimal treatment of MRSA bacteremia due to strains with 
vancomycin MIC of 1–2 µg/ml, especially in the setting of 
persistent bacteremia on vancomycin therapy with appropri-
ate trough levels. Most important for patients with isolates 
with reduced susceptibility to vancomycin is appropriate 
surgical therapy including debridement of abscesses and 
necrotic infected tissue, and removal of infected hardware 
and catheters. Whether there is a beneﬁ  t to switching patients 
to daptomycin is remains speculative, and should be inves-
tigated in clinical trials.
Table 1 Daptomycin summary information
Structure Cyclic  lipopeptide
Mechanism of action  Bactericidal, binds cytoplasmic membrane, with resultant depolarization of membrane potential, cellular
 ion  efﬂ  ux and cell death
In vitro activity  Gram positive organisms, including MRSA, VRSA, and vancomycin resistant enterococci
CSLI susceptibility cutoff   1 µg/ml; supplementation to 50 µg/ml Ca2+ required for testing in Muellar-Hinton broth
Pharmacokinetics  Given intravenously,  half- life 8 hours, volume of distribution 100 ml/kg, protein biding 90%–93%, Cmax 94
  µg/ml with 6 mg/kg dose at steady state, linear kinetics through 12 mg/kg
Excretion 78%  renal
Pharmacodynamics  Concentration dependent killing, post-antibiotic effect of 6 hours against S. aureus
US FDA approved indications  Treatment of complicated skin and skin structure infections (caused by susceptible strains of Gram-
  positive microorgansisms, including MSSA and MRSA); S. aureus bacteremia, including those with
  right-sided endocarditis, caused by MSSA and MRSA
FDA approved dose  4 mg/kg q24h for skin and soft tissue infections; 6 mg/kg q24h for bacteremia and endocarditis
Dose for renal dysfunction  Creatinine clearance  30 ml/min: 4 mg/kg q48h for skin and soft tissue infections; 6 mg/kg q48h for bacteremia
  and endocarditis; for hemodialyis, dose after hemodialysis
Adverse reactions  CPK elevation with and without myopathy, transient neuropathy
Drug interactions  HMG-CoA inhibitors
Cost  $171 for 500 mg
Pregnancy Class  B
Abbreviations: CSLI, Clinical and Laboratory Standards Institute; CPK, creative phosphokinase; FDA, Food and Drug Administration; 
MRSA, methicillin-resistant S.aureus; MSSA, methicillin-sensitive S.aureus;   VRSA, vancomycin-resistant S.aureusTherapeutics and Clinical Risk Management 2007:3(4) 683
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Summary of potential role 
of daptomycin for S. aureus 
bacteremia and endocarditis
Key summary information regarding daptomycin use is 
provided in Table 1. Daptomycin provides a needed alterna-
tive to vancomycin in the therapy of S. aureus bacteremia 
and endocarditis for those with either methicillin-resistant 
organisms or intolerance to beta-lactams. Beta-lactams 
such as nafcillin or cefazolin remain the drug of choice for 
bacteremia or endocarditis due to methicillin-susceptible 
S. aureus. Daptomycin would be a drug of choice for pa-
tients with MRSA bacteremia who are either intolerant to 
vancomcyin or infected with daptomycin susceptible strains 
of VRSA. Further clinical studies should be performed 
to deﬁ  ne groups of patients infected with MRSA, based 
on either microbiological characteristics of the infecting 
strain or clinical characteristics of the patients, who could 
potentially beneﬁ  t from daptomycin as compared to vanco-
mycin among organisms that demonstrate in vitro suscepti-
bility to both agents.
References
Arbeit RD, Maki D, Tally FP, et al. 2004. The safety and efﬁ  cacy of 
daptomycin for the treatment of complicated skin and skin-structure 
infections. Clin Infect Dis, 38: 1673–81.
Baddour LM, Wilson WR, Bayer AS, et al. 2005. Infective endocarditis: 
Diagnosis, antimicrobial therapy, and management of complica-
tions a statement for healthcare professionals from the Committee 
on rheumatic fever, endocarditis, and kawasaki disease, council 
on cardiovascular disease in the young, and the councils on clini-
cal cardiology, stroke, and cardiovascular surgery and anesthesia, 
American heart association - Executive summary.  Circulation, 
111:3167–84
Benvenuto M, Benziger DP, Yankelev S, et al. 2006. Pharmacokinetics and 
tolerability of daptomycin at doses up to 12 milligrams per kilogram 
of body weight once daily in healthy volunteers. Antimicrob Agents 
Chemother, 50:3245–9
Carpenter CF, Chambers HF. 2004. Daptomycin: Another novel agent for 
treating infections due to drug-resistant gram-positive pathogens. Clin 
Infect Dis, 38:994–1000.
CDC. 2002. Staphylococcus aureus resistant to vancomycin – United States, 
2002. MMWR. Morbidity and mortality weekly report, 51:565–7.
CDC. 2004. Community-associated methicillin-resistant Staphylococcus 
aureus Infections in Paciﬁ  c Islanders – Hawaii, 2001–2003. MMWR. 
Morbidity and mortality weekly report, 53:767–70.
Cha R, Brown WJ, Rybak MJ, 2003. Bactericidal activities of daptomycin, 
quinupristin-dalfopristin, and linezolid against vancomycin-resistant 
Staphylococcus aureus in an in vitro pharmacodynamic model with 
simulated endocardial vegetations. Antimicrob Agents Chemother, 
47:3960–3.
Chang F-Y, MacDonald BB, Peacock Jr JE, et al. 2003a. A prospective 
multicenter study of Staphylococcus aureus bacteremia: Incidence of 
endocarditis, risk factors for mortality, and clinical impact of methicillin 
resistance. Medicine, 82:322–32
Chang F-Y, Peacock Jr JE, Musher DM, et al. 2003b. Staphylococcus 
aureus bacteremia: Recurrence and the impact of antibiotic treatment 
in a prospective multicenter study. Medicine, 82:333–9
Chirouze C, Cabell CH, Fowler VG Jr, et al. 2004. Prognostic factors in 61 
cases of Staphylococcus aureus prosthetic valve infective endocarditis 
from the international collaboration on endocarditis merged database. 
Clin Infect Dis, 38:1323–7.
[CLSI] Clinical and Laboratory Standards Institute. 2006. Performance 
Standards for Antimicrobial Susceptibility Testing: 16th Informational 
Supplement. CLSI document M100-S16. Wayne, PA: NCCLS
Cosgrove SE, Sakoulas G, Perencevich EN, et al. 2003. Comparison of 
mortality associated with methicillin-resistant and methicillin-suscep-
tible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect 
Dis, 36:53–59.
Cubist Pharmaceuticals Inc., 2006. Cubicin full prescribing information. 
Accessed 25 January, 2007. URL: http://www.cubicin.com/2006_
full_pi.pdf
Cui L, Tominaga E, Neoh H-M, Hiramatsu K. 2006. Correlation between 
reduced daptomycin susceptibility and vancomycin resistance in 
vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents 
Chemother, 50:1079–82.
DeRyke CA, Sutherland C, Zhang B. 2006. Serum bactericidal activities of 
high dose daptomycin with and without coadministration of gentamicin 
against isolates of Staphylococcus aures and Enterococcus species. 
Antimicrob Agents Chemother 50:3529–34.
Edwards CM, King K, Garcia RJ. 2006. Early-onset rhabdomyolysis associ-
ated with daptomycin. Infect Dis Clin Pract, 14:327–8.
Fortún J, Grill F, Martin-Dávila P, et al. 2006. Treatment of long-term 
intravascular catheter-related bacteraemia with antibiotic-lock therapy 
J Antimicrob Chemother, 58:816–821.
Fowler VG Jr, Boucher HW, Corey GR, et al. 2006. Daptomycin versus 
standard therapy for bacteremia and endocarditis caused by Staphylo-
coccus aureus. N Engl J Med, 355:653–65.
Fowler VG Jr, Miro JM, Hoen B, et al. 2005. Staphylococcus au-
reus endocarditis: A consequence of medical progress. JAMA, 
293:3012–21.
Fowler VG Jr, Olsen MK, Corey GR, et al. 2003. Clinical identiﬁ  ers of 
complicated Staphylococcus aureus bacteremia. Arch Intern Med, 
163:2066–72.
Fowler VG Jr, Sanders LL, Sexton DJ, et al. 1998. Outcome of Staphylococ-
cus aureus bacteremia according to compliance with recommendations 
of infectious diseases specialists: Experience with 244 patients. Clin 
Infect Dis, 27:478–86.
French GL. 2006. Bactericidal agents in the treatment of MRSA infec-
tions – the potential role of daptomycin. J Antimicrob Chemother, 
58:1107–17.
Gemmell CG, Edwards DI, Fraise AP, et al. 2006. Guidelines for the pro-
phylaxis and treatment of methicillin-resistant Staphylococcus aureus 
(MRSA) infections in the UK. J Antimicrob Chemother, 57:589–608. 
Hanberger H, Nilsson LE, Maller R, et al. 1991. Pharmacodynamics of dap-
tomycin and vancomycin on Enterococcus faecalis and Staphylococcus 
aureus demonstrated by studies of initial killing and postantibiotic effect 
and inﬂ  uence of Ca2+ and albumin on these drugs. Antimicrob Agents 
Chemother, 35:1710–16.
Hayden MK, Rezai K, Hayes RA, et al. 2005. Development of daptomycin 
resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin 
Micro, 43:5285–7.
Hidayat LK, Hsu DI, Quist R, et al. 2006. High-dose vancomycin therapy 
for methicillin-resistant Staphylococcus aureus infections. Arch Int 
Med, 166:2138–44.
Jevons MP. 1961. “Celbenin”-resistant Staphylococci. BMJ, 1:124–5.
Kazory A, Dibadj K, Weiner ID. 2006. Rhabdomyolysis and acute renal 
failure in a patient treated with daptomycin. J Antimicrob Chemother 
57:578–9.
Khatib R, Johnson LB, Fakih MG, et al 2006. Persistence in staphylococcus 
aureus bacteremia: Incidence, characteristics of patients and outcome. 
Scand J Infect Dis, 38:7–14.
Khatib R, Riederer K, Saeed S, et al. 2005. Time to positivity in Staphy-
lococcus aureus bacteremia: Possible correlation with the source and 
outcome of infection. Clin Infect Dis, 41:594–8.Therapeutics and Clinical Risk Management 2007:3(4) 684
Bamberger
Khatib, R, Saeed S, Sharma M, et al. 2006. Impact of initial antibiotic choice 
and delayed appropriate treatment on the outcome of Staphylococcus 
aureus bacteremia. Eur J Clin Microbio Infect Dis, 25:181–5.
Lamp KC, Rybak MJ, Bailey EM, et al. 1992. In vitro pharmocodynamic 
effects on concentration, pH, and growth phase, on serum bacteri-
cidal activities, of daptomycin and vancomycin. Antimicrob Agents 
Chemother 36:2709–24.
LaPlante KL, Rybak MJ. 2004. Impact of high-inoculum Staphylococcus 
aureus on the activities of nafcillin, vancomycin, linezolid, and dapto-
mycin, alone and in combination with gentamicin, in an in vitro phar-
macodynamic model. Antimicrob Agents Chemother, 48:4665–72.
Levine DP, Fromm BS, Reddy BR. 1991. Slow response to vancomycin 
or vancomycin plus rifampin in methicillin-resistant Staphylococcus 
aureus endocarditis. Ann Intern Med, 115:674–80.
Lodise TP, McKinnon PS, Swiderski L, et al. 2003. Outcomes analysis 
of delayed antibiotic treatment for hospital-acquired Staphylococcus 
aureus bacteremia. Clin Infect Dis, 36:1418–23.
Luperchio SA, Mortin LI, Silverman JA. 2006. MIC Shifts in patients 
treated for Staphylococcus aureus bacteremia and infective endocardi-
tis. Abstract L-1206. Program and abstracts of the 46th ICAAC. ASM, 
Washington D.C.
Mangili A, Bica I, Snydman DR, et al. 2005. Daptomycin-resistant, 
methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect 
Dis, 40:1058–60.
Markowitz N, Quinn EL, Saravolitz LD. 1992. Trimethoprim 
sulfamethoxasole compared with vancomycin for the treatment of 
Staphylococcus aureus infection. Ann Intern Med, 117: 390–8.
Mermel LA, Farr BM, Sheretz RJ, et al. 2001. Guidelines for the management 
of intravascular catheter-related infections. Clin Infect Dis, 32:1249–72.
McKinnon PS, Kreuger TS, Lamp KC, et al 2006. Determinants of clini-
cal outcomes in patients treated with daptomycin for Gram-positive 
infection. Abstract K–782. Program and abstracts of the 46th ICAAC. 
ASM, Washington D.C.
Miro JM, Arguera I, Cabell CH, et al 2005. Staphylococcus aureus native 
valve infective endocarditis: Report of 566 episodes from the Inter-
national Collaboration on Endocarditis Merged Database. Clin Infect 
Dis, 41:507–14.
Moise-Broder P, El-Fawal N, Forrest A, et al. 2006. Relationship of prior 
vancomycin use and daptomycin MICs in patients with MRSA bacte-
remia. Abstract C2–1151. Program and abstracts of the 46th ICAAC. 
ASM, Washington D.C.
Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. 2004. Acces-
sory gene regulator group II polymorphism in methicillin-resistant 
Staphylococcus aureus is predictive of failure of vancomycin therapy. 
Clin Infect Dis, 38:1700–5.
Moran GJ, Krishnadasan A, Gorwitz RJ, et al. 2006. Methicillin-resistant 
S. aureus infections among patients in the emergency department. 
N Engl J Med, 355:666–74.
NNIS System. 2004. National nosocomial infections surveillance (NNIS) 
system report, data summary from January 1992 through June 2004, 
issued October 2004. Am J Infect Control, 32:470–85.
Noskin GA, Rubin RJ, Schentag JJ. 2005. The burden of Staphylococcus 
aureus infections on hospitals in the United States. Arch Intern Med, 
165:1756–61.
Oleson Jr FB, Berman CL, Kirkpatrick JB, et al. 2000. Once-daily dosing 
in dogs optimizes daptomycin safety. Antimicrob Agents Chemother, 
44: 2948–53.
Paez AS, Brown RB, Wilk PA, et al. 2006. Rapid loss of daptomycin 
susceptibility in methicillin-resistant Staphylococcus aureus blood 
culture isolates from an infective endocarditis patient. Infect Dis Clin 
Practice, 14:322–4.
Patel JB, Jevitt LA, Hageman J, et al. 2006. An association between reduced 
susceptibility to daptomycin and reduced susceptibility to vancomycin 
in Staphylococcus aureus. Clin Infect Dis, 42:1652–3.
Rosen AB, Fowler VG Jr, Corey GR, et al 1999. Cost-effectiveness of 
transesophageal echocardiography to determine the duration of therapy 
for intravascular catheter-associated Staphylococcus aureus bacteremia. 
Ann Intern Med, 130:810–20.
Sakoulas G, Alder J, Thauvin-Eliopoulos C, et al. 2006. Induction of 
daptomycin heterogeneous susceptibility in Staphylococcus aureus by 
exposure to vancomycin. Antimicrob Agents Chemother, 50:1581–5.
Sakoulas G, Eliopoulos GM, Moellering RC Jr, et al. 2002. Accessory gene 
regulator (agr) locus in geographically diverse Staphylococcus aureus 
isolates with reduced susceptibility to vancomycin. Antimicrob Agents 
Chemother, 46:1492–502. 
Segreti JA, Crank CW, Finney MS. 2006. Daptomycin for the treatment of 
Gram-positive bacteremia and infective endocarditis: a retrospective 
case series of 31 patients. Pharmacotherapy, 26: 347–52.
Seybold U, Kourbatova EV, Johnson JG, et al 2006. Emergence of 
community-associated methicillin-resistant Staphylococcus aureus 
USA300 genotype as a major cause of health care-associated blood 
stream infections. Clin Infect Dis, 42:647–56. 
Silverman JA, Mortin LI, Vanpraagh AD, et al. 2005. Inhibition of dapto-
mycin by pulmonary surfactant: in vitro modeling and clinical impact. 
J Infect Dis, 191:2149–52.
Small PM, Chambers HF. 1990. Vancomycin for Staphylococcus aureus 
endocarditis in intravenous drug users. Antimicrob Agents Chemother, 
34:1227–31.
Tally FP, DeBruin MF, 2000. Development of daptomycin for Gram-positive 
infections. J Antimicrob Chemother 46:523–6.
Tsuji BT, Rybak MJ. 2005. Short-course gentamicin in combination with 
daptomycin or vancomycin against Staphylococcus aureus in an in 
vitro pharmacodynamic model with simulated endocardial vegetations. 
Antimicrob Agents Chemother, 49:2735–45.
Vikram HR, Havill NL, Koeth LM, et al. 2005. Clinical progression of 
methicillin-resistant Staphylococcus aureus vertebral osteomyeltis 
associated with reduced susceptibility to daptomycin. J Clin Micro, 
43:5383–7.
Voycih JM, Braughton KR, Surdevant DE, et al. 2005. Insights into mecha-
nisms used by Staphylococcus aureus to avoid destruction by human 
neutrophils. J Immunol, 175:3907–19.